These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17957688)

  • 1. [Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma].
    Fieth C; Kebig A; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):442-5. PubMed ID: 17957688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration].
    Mohr-Andrä M; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):437-40. PubMed ID: 17957687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular target therapy for colonic neoplasms].
    Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
    Peter S; Hausmann N; Schuster A; Boehm HF
    Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab.
    Kazazi-Hyseni F; Beijnen JH; Schellens JH
    Oncologist; 2010; 15(8):819-25. PubMed ID: 20688807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer: The nuances of therapy.
    Ellis LM; Reardon DA
    Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
    [No Abstract]   [Full Text] [Related]  

  • 7. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
    Akman A; Yilmaz E; Mutlu H; Ozdogan M
    Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.
    El Maalouf G; Mitry E; Lacout A; Lièvre A; Rougier P
    J Neurol; 2008 Feb; 255(2):295-6. PubMed ID: 18283405
    [No Abstract]   [Full Text] [Related]  

  • 9. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
    Krämer I; Lipp HP
    Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of bevacizumab in mild haemophilia B.
    Lambert C; Deneys V; Pothen D; Hermans C
    Thromb Haemost; 2008 May; 99(5):963-4. PubMed ID: 18449429
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted drugs for metastatic renal cell carcinoma.
    Motzer RJ; Basch E
    Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy as palliation in advanced colon cancer.
    J Support Oncol; 2007 Feb; 5(2):66. PubMed ID: 17348358
    [No Abstract]   [Full Text] [Related]  

  • 14. Hand eruption after intravenous administration of bevacizumab.
    Ruiz V; Garcia-Muret MP; Alomar A
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):238-9. PubMed ID: 20477919
    [No Abstract]   [Full Text] [Related]  

  • 15. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.
    Coriat R; Mir O; Leblanc S; Ropert S; Brezault C; Chaussade S; Goldwasser F
    Inflamm Bowel Dis; 2011 Jul; 17(7):1632. PubMed ID: 21674721
    [No Abstract]   [Full Text] [Related]  

  • 16. Accrual delayed in adjuvant bevacizumab trial.
    Tuma RS
    J Natl Cancer Inst; 2006 Apr; 98(7):439-40. PubMed ID: 16595779
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
    Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
    Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
    Zondor SD; Medina PJ
    Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of bevacizumab for the treatment of colorectal cancer.
    Beaumont I
    Int J Palliat Nurs; 2010 Dec; 16(12):576. PubMed ID: 21240099
    [No Abstract]   [Full Text] [Related]  

  • 20. Caution in adding bevacizumab in the adjuvant treatment of breast cancer.
    Ziogas D; Roukos D
    Ann Surg Oncol; 2010 Feb; 17(2):653-4; author reply 655-6. PubMed ID: 19888632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.